Shishir Maithel, MD
Surgical Oncology · Chicago, ILNPI 1750540233
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,372 of the $16,131 with a category attached, or 89.1%. 15 manufacturers reported payments, led by AstraZeneca at 59.0% of the total. Reporting peaked in 2024 at $6,891 and has fallen 55.9% since, to $3,037 in 2025.
Across 31 payments — averaging $520.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- F. Hoffmann-la Roche AG$3K
- Astrazeneca UK Limited$1K
- Genentech, Inc.$845
- Intera Oncology, Inc$612
- Jazz Pharmaceuticals Inc.$264
- plus $763 from 9 others
Across 4 payments — averaging $89,928 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$360K
What the payments were for
- Consulting fees$14,37289%
- Food & beverage$1,75911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $9,517 |
| F. Hoffmann-la Roche AG | 1 | $2,787 |
| Astrazeneca UK Limited | 1 | $1,343 |
| Genentech, Inc. | 1 | $845 |
| Intera Oncology, Inc | 3 | $612 |
| Jazz Pharmaceuticals Inc. | 3 | $264 |
| Medtronic | 2 | $240 |
| Integra Lifesciences Corporation | 1 | $170 |
| Boston Scientific | 1 | $133 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $69 |
| Intuitive Surgical | 1 | $45 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Taiho Oncology, Inc. | 1 | $25 |
| AbbVie | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$3,073
- TECENTRIQ$2,787
- Intera 3000 Implantable Pump$413
- Signia$240
- CODMAN CERTAS$170
- CUSA CLARITY$170
- SPYGLASS$133
- ZIIHERA$121
- INTERA$112
How this compares
$16,131 in reported general payments places this provider in the 85th percentile of 55 surgical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 32 | $414 |
| Gabapentin | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Chicago
- Fadi DahdalehChicago$198K
- Nora HansenChicago$41K
- Jeffrey WayneChicago$38K
- David BentremChicago$34K
- Mecker MollerChicago$25K
- Aslam EjazChicago$16K
- Ryan MerkowChicago$16K
- Xavier KeutgenChicago$13K
- Alejandra Perez TamayoChicago$6K
- Juliet LumatiChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.